GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Micro Biosystems Inc (NAS:RPID) » Definitions » Capex-to-Revenue

RPID (Rapid Micro Biosystems) Capex-to-Revenue : 0.03 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rapid Micro Biosystems Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Rapid Micro Biosystems's Capital Expenditure for the three months ended in Sep. 2024 was $-0.22 Mil. Its Revenue for the three months ended in Sep. 2024 was $7.60 Mil.

Hence, Rapid Micro Biosystems's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.03.


Rapid Micro Biosystems Capex-to-Revenue Historical Data

The historical data trend for Rapid Micro Biosystems's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Micro Biosystems Capex-to-Revenue Chart

Rapid Micro Biosystems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
0.10 0.04 0.14 0.39 0.08

Rapid Micro Biosystems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.07 0.10 0.07 0.03

Competitive Comparison of Rapid Micro Biosystems's Capex-to-Revenue

For the Medical Devices subindustry, Rapid Micro Biosystems's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Micro Biosystems's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Rapid Micro Biosystems's Capex-to-Revenue falls into.



Rapid Micro Biosystems Capex-to-Revenue Calculation

Rapid Micro Biosystems's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.845) / 22.519
=0.08

Rapid Micro Biosystems's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.223) / 7.604
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rapid Micro Biosystems  (NAS:RPID) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Rapid Micro Biosystems Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rapid Micro Biosystems's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Micro Biosystems Business Description

Traded in Other Exchanges
N/A
Address
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, USA, 01854
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Executives
Melinda Litherland Pei director 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Sean M Wirtjes officer: Chief Financial Officer C/O VARIAN, INC., 3120 HANSEN WAY, M/S D-083, PALO ALTO CA 94304-1030
Spignesi Robert G. Jr. director, officer: President and CEO C/O RAPID MICRO BIOSYSTEMS, INC., 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Richard S Kollender director C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
Kennedy Lewis Capital Partners Master Fund Ii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Darren Richman 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Klm Gp Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Investment Management Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Management Lp 10 percent owner 225 LIBERTY STREET, SUITE 4210, NEW YORK NY 10281
David Chene 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Capital Partners Master Fund Iii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Iii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Holdings Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120